THU-144-Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis
Wan‐Long Chuang(Kaohsiung Medical University), Alessandra Mangia(Casa Sollievo della Sofferenza), Anuj Gaggar(Gilead Sciences (United States)), Chen‐Hua Liu(National Taiwan University Hospital), Luigi Biancone(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Tsung‐Hui Hu(National Sun Yat-sen University), Meghan E. Sise(Harvard University), Svetlana Markova, Sophia Lu(Myovant Sciences (United States)), Cheng‐Yuan Peng(China Medical University), Wei‐Wen Su(Taichung Veterans General Hospital), Christophe Moreno(Genfit (France)), R. Hyland(Gilead Sciences (United States)), Hadas Dvory-Sobel, Peter Buggisch(Institute for Interdisciplinary Medicine), Anu Osinusi(Gilead Sciences (United States))
Cited by 7
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653